• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Clinical effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.

作者信息

Akizawa Tadao, Koshikawa Shozo, Iida Nobutoshi, Marumo Fumiaki, Akiba Takashi, Kawaguchi Yoshindo, Imada Akio, Yamazaki Chikao, Suzuki Masashi, Tubakihara Yoshiharu

机构信息

Center for Purification Therapy, Wakayama Medical University, Wakayama City, Japan.

出版信息

Nephron. 2002 Apr;90(4):384-90. doi: 10.1159/000054725.

DOI:10.1159/000054725
PMID:11961396
Abstract

Orthostatic hypotension is one of the major factors interfering with everyday activities in hemodialysis patients, but there has been no effective agent for treating it. In order to clarify the clinical effects of L-threo-3,4-dihydroxyphenylserine (L-DOPS) on orthostatic hypotension of hemodialysis patients, we conducted a randomized, double-blind comparative trial. 149 regular hemodialysis patients with orthostatic hypotension were randomly allocated to three groups and L-DOPS at doses of 400 mg, 200 mg or placebo was orally administrated to each group 30 min before starting every hemodialysis for 4 weeks. Changes of blood pressure (BP) in orthostatic hypotension immediately after completion of hemodialysis and symptoms related to orthostatic hypotension were compared between the three groups. In the 400-mg group, systolic and diastolic BP after standing increased significantly and the drop of mean BP after standing was also reduced compared with pretreatment levels. No such changes were observed in the placebo group. Fatiguability, malaise/weakness, dizziness and light-headed feeling, the interdialytic symptoms commonly observed in hemodialysis patients who developed orthostatic hypotension, were improved to a significant extent in the L-DOPS group compared with the placebo group. In particular, the improvement was more remarkable for the L-DOPS 400-mg group than the placebo group in patients with diabetic nephropathy, lower systolic BP after standing, and the long duration type of orthostatic hypotension. The incidence of adverse events was comparable between the three groups, and all recovered after discontinuation of L-DOPS or concomitantly administered drugs, or without any treatment. These findings indicate that L-DOPS taken before hemodialysis prevents orthostatic hypotension in patients undergoing hemodialysis, and is also effective for the interdialytic symptoms related to orthostatic hypotension.

摘要

相似文献

1
Clinical effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.
Nephron. 2002 Apr;90(4):384-90. doi: 10.1159/000054725.
2
Effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.L-苏糖型-3,4-二羟基苯丝氨酸对血液透析患者直立性低血压的影响。
Am J Nephrol. 2002 Jul-Aug;22(4):338-46. doi: 10.1159/000065224.
3
L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.L-苏糖型二羟基苯丝氨酸(L-苏糖型-DOPS;屈昔多巴)用于治疗神经源性直立性低血压:一项针对多系统萎缩和单纯自主神经功能衰竭的多国、多中心、剂量范围研究。
Clin Auton Res. 2001 Aug;11(4):235-42. doi: 10.1007/BF02298955.
4
Midodrine hydrochloride and L-threo-3,4-dihydroxy-phenylserine preserve cerebral blood flow in hemodialysis patients with orthostatic hypotension.
Ther Apher Dial. 2007 Feb;11(1):49-55. doi: 10.1111/j.1744-9987.2007.00455.x.
5
The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial.3,4-DL-苏式二羟基苯丝氨酸治疗神经源性直立性低血压:一项随机、安慰剂对照、交叉试验。
Neurology. 1999 Dec 10;53(9):2151-7. doi: 10.1212/wnl.53.9.2151.
6
Norepinephrine precursor therapy in neurogenic orthostatic hypotension.去甲肾上腺素前体疗法治疗神经源性直立性低血压
Circulation. 2003 Aug 12;108(6):724-8. doi: 10.1161/01.CIR.0000083721.49847.D7. Epub 2003 Jul 28.
7
The effects of the noradrenaline precursor, L-threo-3,4-dihydroxyphenylserine, in children with orthostatic intolerance.去甲肾上腺素前体L-苏式-3,4-二羟基苯丝氨酸对体位性不耐受儿童的影响。
Clin Auton Res. 1996 Aug;6(4):189-93. doi: 10.1007/BF02291133.
8
DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension.DL-苏式-3,4-二羟基苯丝氨酸对直立性低血压无升压作用。
Clin Pharmacol Ther. 1984 Sep;36(3):302-6. doi: 10.1038/clpt.1984.179.
9
Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension.患者神经源性直立性低血压时,L-苏-3,4-二羟基苯丝氨酸(羟多巴)大量转化为去甲肾上腺素。
Clin Auton Res. 2019 Feb;29(1):113-117. doi: 10.1007/s10286-018-0564-5. Epub 2018 Sep 18.
10
Improved orthostatic tolerance in familial amyloidotic polyneuropathy with unnatural noradrenaline precursor L-threo-3,4-dihydroxyphenylserine.使用非天然去甲肾上腺素前体L-苏式-3,4-二羟基苯丝氨酸改善家族性淀粉样多神经病患者的直立耐受能力。
J Auton Nerv Syst. 1997 Jan 12;62(1-2):63-71. doi: 10.1016/s0165-1838(96)00110-5.

引用本文的文献

1
Interventions for fatigue in people with kidney failure requiring dialysis.肾衰竭需透析患者的疲劳干预措施。
Cochrane Database Syst Rev. 2023 Aug 31;8(8):CD013074. doi: 10.1002/14651858.CD013074.pub2.
2
Droxidopa in neurogenic orthostatic hypotension.屈昔多巴治疗神经源性直立性低血压。
Expert Rev Cardiovasc Ther. 2015;13(8):875-91. doi: 10.1586/14779072.2015.1057504. Epub 2015 Jun 19.
3
Current pharmacological management of hypotensive syndromes in the elderly.老年人低血压综合征的当前药物治疗
Drugs Aging. 2015 May;32(5):337-48. doi: 10.1007/s40266-015-0263-z.